This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Zeven, Exulett (EU), RQ-00000002, Xydalba (EU)
Description: Dalbavancin, a novel next-generation glycopeptide agent, belongs to the same class as vancomycin, the most widely-used and one of the few treatments available to patients infected with the most difficult-to- treat strains of Staph: MRSA (methicillin-resistant Staphylococcus aureus) and MRSE (methicillin-resistant Staphylococcus epidermidis). Dalbavancin has been specifically designed as an improved alternative to vancomycin. In vitro studies have shown that in addition to being potent against clinically important Gram-positive bacteria, it is also bactericidal (i.e., kills bacteria rather than merely inhibiting their growth).
In September 2005, Pfizer completed its acquisition of Vicuron Pharmaceuticals. Through the transaction, Pfizer acquired dalbavancin.
In Japan, RaQualia, formerly Pfizer Nagoya Laboratories, has licensing rights for development and commercialization of dalbavancin.
In December 2009, Pfizer completed its sale of Vicuron, including dalbavancin, to Durata Therapeutics.
RaQualia and Durata
In December 2010, RaQualia Pharma announced that it has entered into an agreement with Durata Therapeutics. Under the terms of the agreement, Durata obtained RaQualia's Japanese rights to develop and commercialize of dalbavancin. Durata already holds the rights to develop and commercialize dalbavancin outside Japan. In exchange for the Japanese rights to dalbavancin, RaQualia will receive an upfront payment, development milestones and royalties on sales in Japan.
Durata and Angelini
Durata Therapeutics announced that its Dutch subsidiary, Durata...See full deal structure in Biomedtracker
Partners: RaQualia Pharma Inc. ACRAF SpA (Gruppo Angelini) Cardiome Pharma Corp.
Additional information available to subscribers only: